Not exact matches
PARP (Poly ADP - Ribose Polymerase) inhibitors, such as
olaparib, are targeted drugs that block an enzyme involved in many functions in the cell,
including the repair of DNA damage.
The FDA has expanded the approval of the PARP inhibitor
olaparib (Lynparza) to
include the treatment of patients with metastatic breast cancer who have a mutated BRCA gene.
In ovarian or breast cancers,
olaparib resistance has been associated with HRR restoration,
including by BRCA2 mutation reversion.